10/18/2024

Janusmed sex and gender

Janusmed sex and gender – L1 protein, human papillomavirus (HPV) type 6, virus-like particles, recombinant

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Vaccine for human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52 and 58)

Vaccine for human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52 and 58)

Class : A

Show all info

Print

Contact us

  1. Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.

  2. Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.

  3. Gardasil 9 (human papillomavirus vaccine, types 6, 11, 16, 18, 31,33, 45, 52, 58). Summary of Product Characteristics. European Medicines Agency (EMA); 2017.

  4. Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017

  1. Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.
  2. Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.
  3. Gardasil 9 (human papillomavirus vaccine, types 6, 11, 16, 18, 31,33, 45, 52, 58). Summary of Product Characteristics. European Medicines Agency (EMA); 2017.
  4. Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017
A A
A A

Vaccine for human papillomavirus (types 6, 11, 16, 18)

Vaccine for human papillomavirus (types 6, 11, 16, 18)

Class : A

Show all info

Print

Contact us

  1. Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.

  2. Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.

  3. Gardasil/Silgard. Summary of Product Characteristics. European Medicines Agency (EMA). 2017.

  4. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-43.

  5. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009;5:696-704.

  6. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364:401-11.

  7. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27.

  8. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365:1576-85.

  9. Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017

  1. Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.
  2. Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.
  3. Gardasil/Silgard. Summary of Product Characteristics. European Medicines Agency (EMA). 2017.
  4. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-43.
  5. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009;5:696-704.
  6. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364:401-11.
  7. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27.
  8. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365:1576-85.
  9. Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017